Hemgenix 1 × 1013 genome copies/mL suspension for intravenous infusion Images
Generic Name: etranacogene dezaparvovec
This medication has been identified as Hemgenix 1 × 1013 genome copies/mL suspension for intravenous infusion. It is supplied by CSL Behring.
Hemgenix is used in the treatment of Hemophilia B and belongs to the drug class miscellaneous coagulation modifiers. Hemgenix 1 × 1013 genome copies/mL suspension for intravenous infusion is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Hemgenix
- Generic Name
- etranacogene dezaparvovec
- Strength
- 1 × 1013 genome copies/mL suspension for intravenous infusion
- Availability
- Prescription only
- Drug Class
- Miscellaneous coagulation modifiers
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- CSL Behring
- National Drug Code (NDC)
More about Hemgenix (etranacogene dezaparvovec)
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous coagulation modifiers
Patient resources
- Hemgenix drug information
- Hemgenix (101-105 kg)
- Hemgenix (106-110 kg)
- Hemgenix (111-115 kg)
- Hemgenix (116-120 kg)
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.